Xvivo Perfusion AB (CHIX:XVIVOS) Retained Earnings: kr369.5 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:XVIVOS Xvivo Perfusion AB CHIX:XVIVOS
87 GF Score
Price kr302.60
GF Value kr504.43
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Retained Earnings?

Xvivo Perfusion AB CHIX:XVIVOS 87 Retained Earnings is kr369.5 Mil as of Jun. 2026. GuruFocus rates CHIX:XVIVOS with a GF Score™ of 87/100 and a GF Value™ of kr504.43. The stock has 2 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Xvivo Perfusion AB's retained earnings for the quarter that ended in Jun. 2026 was kr369.5 Mil.

Xvivo Perfusion AB's quarterly retained earnings increased from Dec. 2025 (kr316.9 Mil) to Mar. 2026 (kr353.2 Mil) and increased from Mar. 2026 (kr353.2 Mil) to Jun. 2026 (kr369.5 Mil).

Xvivo Perfusion AB's annual retained earnings increased from Dec. 2023 (kr119.6 Mil) to Dec. 2024 (kr291.8 Mil) and increased from Dec. 2024 (kr291.8 Mil) to Dec. 2025 (kr316.9 Mil).


Xvivo Perfusion AB  (CHIX:XVIVOs) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Xvivo Perfusion AB Retained Earnings Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Retained Earnings Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.28 27.75 119.57 291.76 316.91

Xvivo Perfusion AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 280.92 285.26 316.91 353.20 369.49
CHIX:XVIVOS
87GF Score
Xvivo Perfusion AB CHIX:XVIVOS
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of kr369.5 Mil mean?
Xvivo Perfusion AB (CHIX:XVIVOS) has a Retained Earnings of kr369.5 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Retained Earnings too high?
Xvivo Perfusion AB's current Retained Earnings is kr369.5 Mil. Overall, Xvivo Perfusion AB has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Retained Earnings compare to ABT and SYK?
Xvivo Perfusion AB's Retained Earnings of kr369.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Retained Earnings is kr369.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Xvivo Perfusion AB (CHIX:XVIVOS) has a current Retained Earnings of kr369.5 Mil. The stock's GF Value™ is kr504.43, compared to a current price of kr302.60 — trading 40% below its estimated fair value. The current Retained Earnings is kr369.5 Mil. Xvivo Perfusion AB's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Xvivo Perfusion AB (CHIX:XVIVOS), the current Retained Earnings is kr369.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (CHIX:XVIVOS) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of kr302.60 is trading 40% below its estimated GF Value™ of kr504.43.

Key valuation signals for CHIX:XVIVOS:

  • Retained Earnings: kr369.5 Mil
  • GF Value™: kr504.43 vs. price of kr302.60 (40% below fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the CHIX:XVIVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
87GF Score

Get the complete analysis for CHIX:XVIVOS

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr302.60
Price
kr504.43
GF Value